However, the gene and protein expression of SEC13 is dramatically increased in colon cancer (CC) patients, which may be related to its glycolytic function, suggesting that SEC13 has opposite effects in different cancer backgrounds (Liu et al. 2022). The gene discussed is SEC13; the disease is malignant colon neoplasm.